BR0314761A - Composto de adenina e seu uso - Google Patents
Composto de adenina e seu usoInfo
- Publication number
- BR0314761A BR0314761A BR0314761-4A BR0314761A BR0314761A BR 0314761 A BR0314761 A BR 0314761A BR 0314761 A BR0314761 A BR 0314761A BR 0314761 A BR0314761 A BR 0314761A
- Authority
- BR
- Brazil
- Prior art keywords
- alkylene
- alkyl
- single bond
- adenine
- unsubstituted
- Prior art date
Links
- 229930024421 Adenine Natural products 0.000 title abstract 3
- -1 Adenine Compound Chemical class 0.000 title abstract 3
- 229960000643 adenine Drugs 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 238000011200 topical administration Methods 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Abstract
"COMPOSTO DE ADENINA E SEU USO". Um medicamento para administração tópica que é eficaz como um agente antialérgico. O medicamento para administração tópica contém como um ingrediente ativo um composto de adenina representado pela fórmula geral (1): [em que o anel A representa um hidrocarboneto aromático mono ou bicíclico de 6 a 10 membros ou um heterociclo aromático mono ou bicíclico de 5 a 10 membros contendo de um a três heteroátomos selecionados entre 0 a 2 átomos de nitrogênio, 0 ou 1 átomo de oxigênio e 0 ou 2 átomo de enxofre; n é um número inteiro de 0 a 2; m é um número inteiro de 0 a 2; R representa halogêno, alquila (não)substituída, etc.; X^ 1^ representa oxigênio, enxofre, NR^ 1^ (R^ 1^ representa hidrogênio ou alquila), ou uma ligação única; Y^ 1^ representa uma ligação única, alquileno, etc.; Y^ 2^ representa uma ligação única, alquileno, etc.; Z representa alquileno; e pelo menos um de Q^ 1^ e Q^ 2^ representa -COOR^ 10^ (em que R^ 10^ representa alquila (não)substituída, etc.), etc.) ou um sal farmaceuticamente aceitável do composto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002283428 | 2002-09-27 | ||
JP2002301213 | 2002-10-16 | ||
PCT/JP2003/012320 WO2004029054A1 (ja) | 2002-09-27 | 2003-09-26 | 新規アデニン化合物及びその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314761A true BR0314761A (pt) | 2005-07-26 |
Family
ID=32044638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314761-4A BR0314761A (pt) | 2002-09-27 | 2003-09-26 | Composto de adenina e seu uso |
Country Status (15)
Country | Link |
---|---|
US (3) | US7754728B2 (pt) |
EP (1) | EP1550662B1 (pt) |
JP (1) | JP4768263B2 (pt) |
KR (1) | KR101111085B1 (pt) |
CN (1) | CN1684966A (pt) |
AU (1) | AU2003271064B2 (pt) |
BR (1) | BR0314761A (pt) |
CA (1) | CA2497765A1 (pt) |
ES (1) | ES2387388T3 (pt) |
MX (1) | MXPA05003193A (pt) |
NO (1) | NO20052038L (pt) |
NZ (1) | NZ539064A (pt) |
TW (1) | TWI349671B (pt) |
WO (1) | WO2004029054A1 (pt) |
ZA (1) | ZA200501920B (pt) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE404561T1 (de) * | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
JP4768263B2 (ja) * | 2002-09-27 | 2011-09-07 | 大日本住友製薬株式会社 | 新規アデニン化合物及びその用途 |
CN1829708A (zh) * | 2003-07-24 | 2006-09-06 | 尤罗塞尔蒂克股份有限公司 | 哌啶化合物和含有它们的药物组合物 |
WO2005092892A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
CN1938307B (zh) | 2004-03-26 | 2010-06-16 | 大日本住友制药株式会社 | 9-取代的8-氧代腺嘌呤 |
CA2607780A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | Purine derivatives |
US20090324551A1 (en) * | 2005-08-22 | 2009-12-31 | The Regents Of The University Of California Office Of Technology Transfer | Tlr agonists |
TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
JPWO2007034881A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
EP1939200A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
WO2007034882A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
EP1939202A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
BRPI0707945A2 (pt) | 2006-02-17 | 2011-05-17 | Pfizer Ltd | derivados de 3-deazapurina como modulares de tlr7 |
EP2700638A1 (en) * | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
WO2008004948A1 (en) * | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
AU2008227128B2 (en) | 2007-02-07 | 2012-12-06 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and uses therefor |
DK2125792T3 (da) * | 2007-02-19 | 2011-03-07 | Glaxosmithkline Llc | Purinderivater som immunomodulatorer |
ATE530549T1 (de) * | 2007-03-19 | 2011-11-15 | Astrazeneca Ab | 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7) |
EP2132209B8 (en) * | 2007-03-19 | 2014-04-16 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
JPWO2008114819A1 (ja) * | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
ES2571533T3 (es) * | 2007-04-27 | 2016-05-25 | Purdue Pharma Lp | Antagonistas de TRPV1 y usos de los mismos |
CN101622251B (zh) * | 2007-04-27 | 2012-07-04 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的盐或其结晶 |
CA2686163A1 (en) | 2007-05-08 | 2008-11-13 | Astrazenca Ab | Imidazoquinolines with immuno-modulating properties |
CN101784548B (zh) | 2007-06-29 | 2013-07-17 | 吉里德科学公司 | 嘌呤衍生物及其作为toll样受体7的调节剂的用途 |
WO2009034386A1 (en) * | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
WO2009091031A1 (ja) * | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
EP2246353A4 (en) | 2008-01-17 | 2011-04-20 | Dainippon Sumitomo Pharma Co | PROCESS FOR PREPARING AN ADENINE COMPOUND |
WO2009099650A2 (en) * | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
WO2009143477A1 (en) * | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
JP5600116B2 (ja) | 2008-12-09 | 2014-10-01 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体のモジュレーター |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
KR101725567B1 (ko) * | 2009-04-28 | 2017-04-10 | 젠야쿠코교가부시키가이샤 | 푸린 유도체 및 이를 사용하는 항종양제 |
JP5913093B2 (ja) | 2009-05-21 | 2016-04-27 | アストラゼネカ アクチボラグ | 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用 |
GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
JP5732453B2 (ja) * | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
AU2010310813B2 (en) * | 2009-10-22 | 2015-06-18 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
WO2011068233A1 (en) * | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
US8680108B2 (en) * | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011079016A1 (en) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
CN103221067B (zh) | 2010-04-30 | 2016-01-06 | 泰勒麦迪克斯公司 | 磷脂药物类似物 |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
IT1401281B1 (it) | 2010-08-05 | 2013-07-18 | Univ Firenze | Preparazione di coniugati fra derivati dell'adenina e proteine allergeniche e loro uso in immunoterapia specifica per il trattamento delle malattie allergiche. |
JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ[4,5−c]キノリン−1−イル誘導体 |
EP2651943B1 (en) | 2010-12-17 | 2017-03-22 | Sumitomo Dainippon Pharma Co., Ltd. | Purine derivatives |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
ES2887303T3 (es) | 2011-04-08 | 2021-12-22 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para el tratamiento de infecciones víricas |
RU2621708C2 (ru) | 2011-06-22 | 2017-06-07 | ПУРДЬЮ ФАРМА Эл. Пи. | Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение |
DK2734186T3 (en) | 2011-07-22 | 2019-01-07 | Glaxosmithkline Llc | COMPOSITION |
BR112014004971B1 (pt) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | compostos heterociclilaminas, sua composição farmacêutica e seus usos |
WO2013068438A1 (en) | 2011-11-09 | 2013-05-16 | Janssen R&D Ireland | Purine derivatives for the treatment of viral infections |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
MX2014014031A (es) | 2012-05-18 | 2015-02-12 | Sumitomo Dainippon Pharma Co Ltd | Compuestos de acido carboxilico. |
US9382211B2 (en) * | 2012-07-10 | 2016-07-05 | Xpd Holdings, Llc | Stabilized multi-functional antioxidant compounds and methods of use |
MX360718B (es) | 2012-07-13 | 2018-11-13 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para el tratamiento de infecciones víricas. |
UA114109C2 (xx) | 2012-08-24 | 2017-04-25 | Піразолопіримідинові сполуки | |
LT2906563T (lt) | 2012-10-10 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui |
MX361585B (es) | 2012-11-16 | 2018-12-11 | Janssen Sciences Ireland Uc | Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas. |
LT2922549T (lt) | 2012-11-20 | 2017-09-11 | Glaxosmithkline Llc | Naujieji junginiai |
RU2640200C2 (ru) | 2012-11-20 | 2017-12-27 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
CN105189468B (zh) | 2013-02-21 | 2018-10-30 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的2-氨基嘧啶衍生物 |
EP2769738B1 (en) * | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
ES2625456T3 (es) * | 2013-03-29 | 2017-07-19 | Janssen Sciences Ireland Uc | Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas |
MX365848B (es) | 2013-05-24 | 2019-06-17 | Janssen Sciences Ireland Uc | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales. |
EP3030563B1 (en) | 2013-06-27 | 2017-08-09 | Janssen Sciences Ireland UC | Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases |
DK3027624T3 (en) | 2013-07-30 | 2019-01-07 | Janssen Sciences Ireland Uc | THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CN113577081A (zh) | 2014-07-11 | 2021-11-02 | 吉利德科学公司 | 用于治疗hiv的toll样受体调节剂 |
ES2835717T3 (es) | 2014-09-16 | 2021-06-23 | Gilead Sciences Inc | Formas sólidas de un modulador de receptor de tipo Toll |
SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
AU2017289418B2 (en) | 2016-07-01 | 2021-06-03 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
BR112019003519A2 (pt) * | 2016-08-29 | 2019-05-21 | F. Hoffmann-La Roche Ag | compostos de sulfonimidoilpurinona 7-substituídos para o tratamento e profilaxia de infecção por vírus |
US10968184B2 (en) | 2016-09-29 | 2021-04-06 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
JP2021035910A (ja) * | 2017-11-01 | 2021-03-04 | 大日本住友製薬株式会社 | 置換プリン化合物 |
JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ. ホフマン-ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
CA3103623A1 (en) | 2018-06-15 | 2019-12-19 | Afecta Pharmaceuticals, Inc. | Ccl5 inhibitors |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
FR3092114B1 (fr) * | 2019-01-28 | 2021-04-30 | Univ Grenoble Alpes | Nouveaux derives de purine et medicaments les comprenant |
CN110063958A (zh) * | 2019-03-12 | 2019-07-30 | 中国药科大学 | N-噻吩-2-次黄嘌呤硫基乙酰胺在抗结核分枝杆菌感染中的医药用途 |
CN109908150A (zh) * | 2019-03-12 | 2019-06-21 | 中国药科大学 | N-苄基-2-次黄嘌呤硫基乙酰胺衍生物在抗结核分枝杆菌感染中的医药用途 |
WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
US20220380371A1 (en) * | 2019-09-20 | 2022-12-01 | Novartis Ag | Mll1 inhibitors and anti-cancer agents |
KR20220132601A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
WO2021154669A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
US20230131192A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
WO2021154663A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
JP2023512204A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
KR20220132593A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
EP4097102A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
KR20220132595A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 C3-치환된 1H-피라졸로[4,3-d]피리미딘 화합물 |
CN112266386B (zh) * | 2020-10-20 | 2022-03-25 | 中山大学 | 一种2-氯腺嘌呤衍生物、制备方法及应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
EP0727427A4 (en) * | 1993-11-05 | 1997-10-15 | Meiji Milk Prod Co Ltd | ANTIBACTERIAL, ANTIFUNGAL AND ANTIVIRAL AGENT |
TW552261B (en) * | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
DE69817393T2 (de) | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
ATE404561T1 (de) * | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
AU2002332776A1 (en) * | 2001-08-30 | 2003-03-18 | Tolemac, Llc | Antiprotons for imaging and termination of undesirable cells |
JP4768263B2 (ja) * | 2002-09-27 | 2011-09-07 | 大日本住友製薬株式会社 | 新規アデニン化合物及びその用途 |
AU2004271972B2 (en) * | 2003-09-05 | 2010-06-03 | Anadys Pharmaceuticals, Inc. | TLR7 ligands for the treatment of hepatitis C |
WO2005092892A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8−オキソアデニン化合物 |
CA2607780A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | Purine derivatives |
US20090324551A1 (en) * | 2005-08-22 | 2009-12-31 | The Regents Of The University Of California Office Of Technology Transfer | Tlr agonists |
JPWO2007034881A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
EP1939202A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW COMPOUND OF ADENINE |
WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
EP2246353A4 (en) * | 2008-01-17 | 2011-04-20 | Dainippon Sumitomo Pharma Co | PROCESS FOR PREPARING AN ADENINE COMPOUND |
WO2009091031A1 (ja) * | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
KR101616396B1 (ko) * | 2008-08-11 | 2016-04-28 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
-
2003
- 2003-09-26 JP JP2004539550A patent/JP4768263B2/ja not_active Expired - Fee Related
- 2003-09-26 MX MXPA05003193A patent/MXPA05003193A/es active IP Right Grant
- 2003-09-26 WO PCT/JP2003/012320 patent/WO2004029054A1/ja active Application Filing
- 2003-09-26 KR KR1020057005129A patent/KR101111085B1/ko not_active IP Right Cessation
- 2003-09-26 CA CA002497765A patent/CA2497765A1/en not_active Abandoned
- 2003-09-26 BR BR0314761-4A patent/BR0314761A/pt not_active IP Right Cessation
- 2003-09-26 NZ NZ539064A patent/NZ539064A/en not_active IP Right Cessation
- 2003-09-26 TW TW092126677A patent/TWI349671B/zh not_active IP Right Cessation
- 2003-09-26 US US10/528,343 patent/US7754728B2/en not_active Expired - Fee Related
- 2003-09-26 EP EP03751284A patent/EP1550662B1/en not_active Expired - Lifetime
- 2003-09-26 ES ES03751284T patent/ES2387388T3/es not_active Expired - Lifetime
- 2003-09-26 AU AU2003271064A patent/AU2003271064B2/en not_active Ceased
- 2003-09-26 CN CNA038229390A patent/CN1684966A/zh active Pending
-
2005
- 2005-03-07 ZA ZA2005/01920A patent/ZA200501920B/en unknown
- 2005-04-26 NO NO20052038A patent/NO20052038L/no not_active Application Discontinuation
-
2010
- 2010-06-03 US US12/793,649 patent/US8148371B2/en not_active Expired - Fee Related
-
2012
- 2012-02-22 US US13/402,850 patent/US20120178743A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200501920B (en) | 2005-11-30 |
US20060052403A1 (en) | 2006-03-09 |
CN1684966A (zh) | 2005-10-19 |
AU2003271064B2 (en) | 2010-06-17 |
AU2003271064A1 (en) | 2004-04-19 |
CA2497765A1 (en) | 2004-04-08 |
ES2387388T3 (es) | 2012-09-21 |
JP4768263B2 (ja) | 2011-09-07 |
MXPA05003193A (es) | 2005-06-08 |
US20120178743A1 (en) | 2012-07-12 |
US7754728B2 (en) | 2010-07-13 |
TWI349671B (en) | 2011-10-01 |
NZ539064A (en) | 2007-09-28 |
JPWO2004029054A1 (ja) | 2006-01-26 |
NO20052038L (no) | 2005-05-24 |
EP1550662A4 (en) | 2007-03-07 |
KR20050062562A (ko) | 2005-06-23 |
TW200413374A (en) | 2004-08-01 |
KR101111085B1 (ko) | 2012-04-12 |
US8148371B2 (en) | 2012-04-03 |
EP1550662A1 (en) | 2005-07-06 |
WO2004029054A1 (ja) | 2004-04-08 |
US20100256118A1 (en) | 2010-10-07 |
EP1550662B1 (en) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314761A (pt) | Composto de adenina e seu uso | |
NO2022019I1 (no) | Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC | |
BRPI0608291A2 (pt) | agente imunossupressor e agente antitumoral que compreendem composto heterocìclico como ingrediente ativo | |
CO5280078A1 (es) | Compuestos | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
MY146514A (en) | Diarylether derivatives as antitumor agents | |
AU2003263878A1 (en) | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | |
BR0311460A (pt) | Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
MD2447G2 (ro) | Compoziţie farmaceutică, utilizarea ei şi metodă de tratare a cefaleei, migrenei, greţurilor şi vomei | |
BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
ATE156119T1 (de) | 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel | |
CO5560555A2 (es) | Cristales de derivado de hidroxinorefedrina | |
BR0311363A (pt) | Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente | |
ES2059755T3 (es) | Derivados organicos de hidrazina para uso farmaceutico. | |
SE0002476D0 (sv) | New compounds | |
NO304486B1 (no) | Oksazolidonderivater og anvendelser derav, og midler og medisinske preparater omfattende slike oksazolidonderivater | |
UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
KR920014818A (ko) | 항균제 | |
BR0112338A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
MX9206930A (es) | Nuevos compuestos | |
ES2123808T3 (es) | Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo. | |
EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
MX9305719A (es) | Agente antiarritmico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: DAINIPPON PHARMACEUTICAL CO., LTD. (JP) Free format text: TRANSFERIDO POR FUSAO DE: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED |
|
B25D | Requested change of name of applicant approved |
Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAINIPPON PHARMACEUTICAL CO., LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014. |